OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI announced on Tuesday that it has acquired Orchestra Bio, a four-year-old artificial intelligence biotech software startup, to strengthen its life sciences business. Financial terms of the transaction were not disclosed by the companies.
OpenAI announced on Tuesday that it has acquired Orchestra Bio, a four-year-old artificial intelligence biotech software startup, to strengthen its life sciences business. Financial terms of the transaction were not disclosed by the companies.
Before the purchase, Orchestra had raised approximately $20 million by 2025 from investors including Andreessen Horowitz, Atria, and 8VC. The startup builds AI agents—autonomous software programs designed to perform specific tasks—that help biotechnology firms manage administrative drug discovery operations, ranging from tracking finances to resolving scheduling conflicts in clinical trials.
OpenAI stated that it is integrating Orchestra's team and technology into Rosalind, its specialized AI model for life sciences research, and the Rosalind Workbench, a tool that helps researchers plan experiments and analyze results. OpenAI reports that Rosalind already serves major industry customers, including Moderna and Novo Nordisk.
The deal reflects a broader trend of major artificial intelligence laboratories building specialized software for major industries like pharmaceuticals. Rather than facing competition from new lab features, Orchestra's team has been absorbed directly into OpenAI.
A concise explanation prepared from the supplied report material. It is a sourced brief, not a claim of original reporting.
The publisher link, attribution and available publication details are preserved so you can check the original report.
3 related WireUnWired pages are available below for additional context.
Original publication: 21 October 2026 02:05
